

## **Statement of the board of directors pursuant to Chapter 19, Section 22 of the Swedish Companies Act (2005:551)**

As the board of directors proposes that the annual general meeting on 19 May, 2022 resolves to authorize the board of directors to resolve on acquisition of own series C shares, the board of directors of BONESUPPORT HOLDING AB, Reg. No. 556802-2171, hereby issues the following statement pursuant to Chapter 19, Section 22 of the Swedish Companies Act.

In accordance with the proposed authorization, the company will be entitled to repurchase a maximum of 639,572 own series C shares for a price which corresponds to the shares quota value of SEK 0.625 per share. The total amount that may be issued upon acquisition pursuant to the authorization amounts thus to SEK 399,732.50.

The nature and scope of the company's business are set forth in the company's articles of association and the annual report for the financial year 2021. The annual report sets forth the company's and the group's financial position as of 31 December 2021. It also sets forth the principles applied with respect to the valuation of the company's and the group's assets, reservations and liabilities. No assets or liabilities have been reported at their fair value pursuant to Chapter 4, Section 14 a, of the Swedish Annual Accounts Act.

According to the annual report for the financial year 2021, the company's unrestricted equity (available profit and unrestricted reserves) amounts to approximately SEK 1 227 million. As per the balance sheet date, 31 December 2021, the company's restricted equity amounted to approximately SEK 41 million. The board of directors has made the assessment that the company's restricted equity will be intact if the proposed authorization to acquire own series C shares is fully exercised.

Even if the proposed repurchase authorization is fully exercised, the impact on the company's and the group's liquidity will be marginal.

The board of directors is of the opinion that acquisition of own series C shares pursuant to the proposed authorization will not affect the company's and the group's ability to meet their short or long term payment obligations. Nor is the exercise of the proposed authorization expected to negatively affect the company's and the group's ability to make commercially justifiable investments. The board of directors is also of the opinion that the company's and the group's equity, after exercise of the proposed authorization for acquisition of own series C shares, will be sufficient seen in relation to the nature, scope and risks of the business operations of the company and the group.

In view of the above and considering such other circumstances, which have come to the board of directors attention, the board of directors is of the opinion, based on an overall assessment of the company's and the group's financial position, that the proposed authorization to resolve on acquisition of own series C shares is justified with respect to the requirements imposed by the nature, scope and risks of the operations in relation to the size

of the company's and the group's equity, as well as the consolidation needs, liquidity and general position of the company and the group.

Therefore, the board of directors considers that the proposed authorization is justified with respect to the requirements set out in Chapter 17, Section 3, paragraph 2 and 3 of the Swedish Companies Act.

---

Lund in April 2022

BONESUPPORT HOLDING AB (PUBL)

The Board of Directors